​​Emerging ADCs and Their Role in Advanced Lung Cancer Treatment​

Antibody drug conjugates are novel agents developed for the treatment of a variety of cancers, including lung cancer. This webinar will describe the mechanism of action of these agents and will inform the audience of the current use and areas of development. Since these agents are very novel, it is important to discuss the unique side effects associated with treatment and the management of these unique toxicities.

Learning Objectives: 
At the end of the webinar, learners will be able to: 

1. Describe and understand the mechanism of action of ADC. 
2. Identify drugs in development and indications. 
3. Differentiate drug-related adverse events and management of side effects. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.